Disadvantages and limitations of neoadjuvant chemotherapy for invasive bladder cancer
10.3969/j.issn.1009-8291.2024.11.018
- VernacularTitle:肌层浸润性膀胱癌新辅助化疗的自身不足与应用局限
- Author:
Hai HUANG
1
;
Xinyuan HU
1
;
Guojun CHEN
2
;
Hailin REN
2
Author Information
1. Graduate School of Qinghai University, Xining 810000
2. Department of Urology, Affiliated Hospital of Qinghai University, Xining 810000, China
- Publication Type:Journal Article
- Keywords:
muscle invasive bladder cancer;
cisplatin;
neoadjuvant chemotherapy;
radical cystectomy;
disadvantage
- From:
Journal of Modern Urology
2024;29(11):1021-1025
- CountryChina
- Language:Chinese
-
Abstract:
For muscle-invasive bladder cancer (MIBC) patients, preoperative neoadjuvant chemotherapy (NAC) can reduce the tumor stage, treat micrometastases, prolong the median survival, and improve the prognosis.However, NAC is associated with side effects such as renal impairment, thromboembolism and drug toxicity.NAC itself suffers from deficiencies such as renal function impairment, thromboembolism, and drug toxicity.Its therapeutic efficacy is affected by factors such as tumor pathology type, DNA repair gene defects, whether it is primary MIBC, and TNM staging, so there are certain limitations in its use.Based on the cisplatin treatment regimen, more and more studies are exploring the limitations and shortcomings of NAC in MIBC treatment regimen.Therefore, this paper provides an overview and outlook of the application of NAC in MIBC treatment.
